Late-breaking clinical trials at TCT 2023
The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco. TCT features cutting-edge research in interventional cardiovascular medicine that directly impacts patient care and how physicians treat heart disease.
The sessions below include three late-breaking trials sessions that highlight the studies that are expected to have the most impact on interventional cardiology and structural heart interventions.
Late-Breaking Clinical Trials: Session I, in Collaboration with the New England Journal of Medicine
Tuesday, Oct. 24, 11 a.m. — 12:28 p.m., Innovation & Clinical Science Theater, Hall B, Exhibition Level, Moscone South
• PARTNER 3 Low-Risk: Five-year clinical and echocardiographic outcomes from the PARTNER 3 Low-Risk Randomized Trial. Presented by Martin Leon.
• EVOLUT Low Risk: Four-year outcomes from the EVOLUT Low Risk Trial. Presented by Michael Reardon.
• WATCH TAVR: Safety and efficacy of left atrial appendage (LAA) occlusion at the time of transcatheter aortic valve replacement. Presented by Samir Kapadia.
• ALIGN-AR: Initial outcomes of the JenaValve Trilogy transcatheter aortic valve replacement system in high-risk patients with symptomatic severe native aortic regurgitation. Presented by Vinod Thourani.
Late-Breaking Clinical Science: Session I, in Collaboration with the Journal of the American College of Cardiology
Tuesday, Oct. 24, 2-3:30 p.m., Innovation & Clinical Science Theater, Hall B, Exhibition Level, Moscone South
• PARTNER 3 Low-Risk: Five-year clinical and echocardiographic outcomes from the PARTNER 3 Low-Risk Randomized Trial. Presented by Rebecca Hahn.
• Tendyne SUMMIT Pivotal Trial: Roll-in and mitral annulus calcification (MAC) arm outcomes. Presenters are Jason Rogers and Vinod Thourani.
• TRILUMINATE Pivotal: Outcomes of Both Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation. Presented by David Adams.
• SWISS-APERO: One-year outcomes after Amulet or Watchman/FLX device for percutaneous left atrial appendage closure pre-specified analysis of the randomized clinical trial. Presented by Roberto Galea.
• EXPAND G4: One-year outcomes with fourth-generation mitral valve transcatheter edge-to-edge repair. Presented by Ralph Stephan von Bardeleben.
Late-Breaking Clinical Trials: Session II, in Collaboration with The Lancet
Wednesday, Oct. 25, 11 a.m. — 12:28 p.m., Innovation & Clinical Science Theater, Hall B, Exhibition Level, Moscone South
• LIFE-BTK: Primary outcomes of the Esprit BTK drug-eluting resorbable scaffold for the treatment of infrapopliteal lesions. Presented by Ramon Varcoe.
• AGENT IDE: Primary outcomes of a pivotal multicenter randomized trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis. Presented by Robert Yeh.
• T-PASS: Less than 1-month dual antiplatelet therapy followed by ticagrelor monotherapy after coronary drug-eluting stent implantation for acute coronary syndrome. Presented by Myeong-Ki Hong.
• PICSO-AMI-I: Pressure-controlled intermittent coronary sinus occlusion (PiCSO) in acute myocardial infarction. Presented by Giovanni Luigi De Maria.
Late-Breaking Clinical Science: Session II, in Collaboration with Circulation
Wednesday, Oct. 25, 2-3:30 p.m., Innovation & Clinical Science Theater, Hall B, Exhibition Level, Moscone South
• Sirolimus-coated balloon versus paclitaxel-coated balloon for the treatment of drug-eluting stent in-stent restenosis. Presented by ShaoLiang Chen.
• COMPARE 60/80 HBR Trial: The primary endpoint results from the randomized, controlled, multi-center trial comparing ultrathin with thin strut stents in high bleeding risk patients with an abbreviated DAPT duration. Presented by Pieter C. Smits.
• PARTHENOPE Trial: Polymer-free amphilimus-eluting stents vs. biodegradable-polymer everolimus-eluting stents in all-comers undergoing PCI 1-year results. Presented by Giovanni Esposito
• Biostemi Randomized Trial: Long-term outcomes with biodegradable Polymer Sirolimus-Eluting stents versus durable polymer everolimus-eluting stents in patients With ST-segment elevation myocardial infarction 5-year follow-up. Presented by Juan F. Iglesias.
• SWEDEHEART National Registry: Long-term clinical outcomes after iFR vs. FFR guided coronary revascularization. Presented by Matthias Götberg.
TCT Late-Breaking Clinical Trials: Session III, in Collaboration with the Journal of the American Medical Association
Thursday, Oct. 26, 11 a.m. — 12:30 p.m.
Innovation & Clinical Science Theater, Hall B, Exhibition Level, Moscone South
• TRISCEND II: A randomized trial of transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Presented by Susheel Kodali.
• TRILUMINATE: Quality of life after transcatheter tricuspid-valve repair vs. medical therapy in patients with severe tricuspid regurgitation. Presented by Suzanne Arnold.
• VIVA: Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annuli. Presented by Josep Rodés-Cabau.
• CLASP IID Trial and Complex Anatomy Registry: One year outcomes from a randomized comparison of transcatheter edge-to-edge repair systems for degenerative mitral regurgitation. Presented by Robert Smith and Firas Zahr.
TCT Late-Breaking Clinical Science: Session III, in Collaboration with the European Heart Journal/EuroIntervention
Thursday, Oct. 26, 2-3:30 p.m., Innovation & Clinical Science Theater, Hall B, Exhibition Level, Moscone South
• RADIANCE Clinical Trial Program: Individual patient-data pooled analysis of endovascular ultrasound renal denervation or a sham procedure at 6 months. Presented by Ajay Kirtane.
• ISAR-DESIRE 3 Trial: Recurrent revascularization after teatment Of drug-eluting stent eestenosis with drug-coated balloon, plain balloon or drug-eluting stent 10-year results. Presented by Tobias Koch.
• DCB-ACS Trial: Drug-coated balloon for acute coronary syndromes, a multi-center randomized non-inferiority trial. Presented by Haibo Jia.
• EPS/TAVR Study: Atrioventricular conduction system changes during transcatheter aortic valve replacement (TAVR), anatomic and electrophysiologic predictors of heart block in prospective 400 patient study. Presented by Alfred Buxton.
• Outcomes of patients with new left bundle branch block following TAVR: Insights from the NCDR STS/ACC TVT Registry. Presented by Nickpreet Singh.
Find the complete listings of the late-breaking TCT 2023 trials.
Find the complete listings for the late-breaking clinical science sessions.
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com